By Connor Hart
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
The San Diego biopharmaceutical company said Monday it will obtain exclusive rights for the drug in all territories worldwide except Japan, where Takeda will reacquire exclusive rights. Under the updated agreement, each company is responsible for development costs in their respective regions, and both companies are eligible to receive royalty payments.
Chief Executive Kyle Gano said the new terms will streamline the collaboration structure, hopefully bringing the treatment to market faster.
Neurocrine and Takeda, which is headquartered in Osaka, Japan, entered an agreement to develop and commercialize compounds for treatment of depression and schizophrenia in 2020.
Osavampator is a potential treatment for major depressive disorder for patients who haven't benefited from treatment with at least one antidepressant in their current episode of depression, Neurocrine said. The company plans to initiate a Phase 3 trial for the drug in the first half.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 27, 2025 17:21 ET (22:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。